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Table 2
Median percentage of Th1 subsets at engraftment (range)
Grade 0-1 aGVHD Grade 2-4 aGVHD P
Total (parent) Th1 cells 15.1% (2.1-28.8) 76.6% (39.5-94.1) 0.03
CLA+ Th1 cells 1.0% (0.2-3.5) 2.9% (0.4-11.2) <0.01
a4b7+ Th1 cells 22.3% (5.7-59) 31.8% (12.7-43.6) 0.07
CLA- a4b7- Th1 cells 76.6% (39.5-94.1) 64.9% (47.3-82.9) 0.03
Abstracts / Biol Blood Marrow Transplant 20 (2014) S45eS56 S51of T cell trafﬁcking. Preliminary results show distinct organ-
speciﬁc patterns of T cell kinetics after AHSCT. These data
allow mathematical modeling of T cell behavior post AHSCT
in a pre-clinical model of cGVHD, enabling interpretation of
in vivo T cell kinetics in peripheral blood of patients under-
going AHSCT with and without cGVHD.46
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Donor Th1 immunity can initiate acute graft-versus-host
disease (aGVHD) after allogeneic hematopoietic cell
transplantation (HCT). Paradoxically, deﬁciency of the Th1
cytokine IFN-g can accelerate aGVHD in animal models. We
hypothesized that Th1 cells can be inﬂammatory (pro-GVHD)Table 1
Variable N (%)
Age 47 y (21-70)
Male 29 (49)
Disease risk
Standard 29 (49)
High 30 (51)
Conditioning
Ablative 33 (56)
Reduced intensity 26 (44)
Donor
Related 43 (72)
Unrelated 16 (28)
Stem cell
Peripheral blood 49 (83)
Other 10 (17)or inhibitory (anti-GVHD/GVL) depending on their expres-
sion of tissue-homing molecules.
From February 2007 to March 2009, patients undergoing
HCT were eligible for an aGVHD biomarker trial at Vanderbilt
University. Circulating Th1 cells (CD4+ IFN-g+) were quanti-
ﬁed in 59 patients at neutrophil engraftment using ﬂow
cytometry. Circulating skin-homing (CLA+), gut-homing
(a4b7+), and conventional (CLA-a4b7-) Th1 cells were
identiﬁed and expressed as a percentage of the total Th1
population.
Table 1 details the patient characteristics (N¼59). Grade 2-4
or 3-4 aGVHD was diagnosed in 46 (78%) and 9 (15%) pa-
tients, respectively. Patients developing grade 2-4 aGVHD
had signiﬁcantly lower percentages of total Th1 cells at
engraftment compared to recipients with grade 0-1 aGVHD
(P¼0.03) (Table 2). Decreasing frequencies of total Th1 cells
predicted increasing severity of aGVHD (OR 1.12; P¼0.01).
However, when accounting for tissue-speciﬁcity, patients
with grade 2-4 aGVHD had increased frequencies of
circulating skin-homing (CLA+) Th1 cells (P<0.01) and gut-
homing (a4b7+) Th1 cells (P¼0.07) but lower conventional
(CLA- a4b7-) Th1 cells (P¼0.03), than patients with grade 0-1
aGVHD (Table 2). The percentage of CLA+ Th1 cells was also
higher in patients with skin-only aGVHD (4.1% vs. 2.8%;
P¼0.05). Adjusting for donor, conditioning, and stem cell
source, lower percentage of total Th1 cells at engraftment
was associated with increased risk for grade 2-4 aGVHD (HR
1.07; P¼0.02). Conversely, increasing percentage of total Th1
cells at engraftment was associated with inferior DFS, when
analyzed as a continuous variable (HR 1.06; P¼0.05) or
categorical variable (Figure 1) (independent of age and dis-
ease risk). aGVHD did not impact survival.
Early Th1 cell expansionwithin the CLA- a4b7- compartment
decreases alloreactivity perhaps due to impaired T cell
migration to target tissue. High percentages of Th1 cells at
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emptive therapies to promote GVL and prevent malignancy
relapse.47
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Background: Mycophenolate mofetil (MMF) is frequently
combined with cyclosporine-A (CSA) as immunosuppression
in CBT. Drug monitoring of MPA, the active MMF metabolite,
is advisable based on variable MMF pharmacokinetics and
the association of low unbound MPA AUCs with increased
aGVHD. This is highly relevant in CBT as aGVHD is a leading
cause of mortality. However, a limited pharmacokinetic
parameter such as MPA troughs is ideal. Additionally, the
toxicity associatedwithMPA troughs is not established and is
of concern in CBT due to the theoretical risk of myelosup-
pression from high levels.
Methods: We evaluated the association between serial
(weeks 1-6) total MPA trough levels and outcomes in double-
unit CBT recipients transplanted 8/2009-11/2012. Intravenous
CSA/MMF commenced on day -3. Trough levels were dichot-
omized into <2 mcg/mL and 2 mcg/mL for the toxicity
analysis (engraftment, gastro-intestinal toxicity as measuredby TPN duration and CMV infection) at each time point. For
the efﬁcacy (aGVHD prevention) analysis, meanweek 1 and 2
trough levels were split at <0.5 vs 0.5 mcg/mL.
Results: Eighty-three patients (median age 44 years, range
1-71) had weekly MPA levels for 6 weeks after CBT. Sixty-
nine (83%) received myeloablative (MA) conditioning and 45
(54%) were CMV seropositive. Median trough levels ranged
0.6-1.3 mcg/mL. Trough levels increased over time (p¼0.03).
Myeloablative (MA) had lower MPA troughs than non-mye-
loablative recipients (p¼0.02). Younger age (0-15 years old)
was associated with lower trough levels (p¼0.002). By
time-dependent Cox regression analysis, there was no
association between troughs and toxicity, and MA recipients
